In episode 75 of the Hyperautomation Minute, Aaron Back discusses recent life sciences innovations that utilize AI and are designed to treat specific ailments. Aaron emphasizes why there must be ethical guidelines in place to ensure that these solutions positively benefit humanity.
Highlights
00:17 — Breakthroughs in science are happening at a rapid pace, mainly in part because of the pandemic. Industries such as manufacturing, retail, healthcare, and life sciences have developed many innovations, which continue to develop even faster due to artificial intelligence (AI).
01:04 — Dr. Jiye Shi, Associate Vice President and Head of Computational Design and Automation Platforms at the Lilly Company, shared a recent breakthrough. The team developed a first-in-class monoclonal antibody designed to treat plaque psoriasis. Stemming from the breakthrough research brought on by alpha fold in the protein folding understanding, Dr. Shi and his team are developing computationally-designed drugs that target specific ailments.
02:47 — AI and data infusion are leading to new efficiencies in biologics manufacturing, shortening the time it takes for these drugs to be released for public use. All of the data is fed into an AI/ML model that outputs a 3D model of the drug-protein, hopefully reducing the testing cycle that is needed.
03:36 — The innovative blend of technology and biology is leading to truly remarkable outcomes. Many of the Cloud Wars Top 10 companies create, expand and build upon these life science solutions.
04:25 — These companies are utilizing their partner’s ecosystems, in conjunction with their customers to co-create innovative solutions, which are positively benefitting humanity.
04:57 — The lines between biology and technology are becoming blurred, which emphasizes the need to put ethical guidelines in place. If scientists and doctors are not careful, these developments could lead to harmful, long-lasting effects, rather than beneficial outcomes that protect humanity.
05:49 — These ethical guidelines should not hinder creativity and progress, but rather, there should be flexibility in these innovations that include underlying ethical parameters, without sacrificing solutions for humanity for the sake of profit.
